Breaking News, Collaborations & Alliances

Pfizer, TransTech Enter RAGE Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer and TransTech Pharma have entered into a license agreement for the development and commercialization of several of TransTech’s small and large molecule compounds. These compounds target the receptor for advanced glycation endproducts (RAGE) and have potential use in the treatment of Alzheimer’s disease (AD). Through the collaboration, Pfizer gains exclusive worldwide rights to develop and commercialize TransTech’s portfolio of RAGE modulators including TTP488, a sma...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters